Navigation Links
Ipsen and Debiopharm Group Announce That Decapeptyl(R)(triptorelin embonate) 6-month Successfully Completes the European Decentralised Procedure for the Treatment of Locally Advanced or Metastatic Prostate Cancer
Date:10/13/2009

hese efficacy results are similar to those obtained previously with repeated administrations of the 1- and 3-month-formulations of triptorelin.

About Debiopharm Group

Debiopharm Group is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses promising biological and small molecule drug candidates. It develops its products for global registration and maximum commercial potential. Once registered, the products are out-licensed to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed four products with global combined sales of $2.6 billion in 2008.

For more information on Debiopharm Group, please visit: http://www.debiopharm.com

About Ipsen

Ipsen is an innovation-driven global specialty pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,200. Its development strategy is based on a combination of specialty medicine, which is Ipsen's growth driver, in targeted therapeutic areas (oncology, endocrinology, neurology and haematology), and primary care products which contribute significantly to its research financing. The location of its four Research & Development centres (Paris, Boston, Barcelona, London) and its peptide and protein engineering platform give the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. More than 800 people in R&D are dedicated to the discovery and development of innovative drugs for patien
'/>"/>

SOURCE Debiopharm Group
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Ipsen and Debiopharm Conclude an Exclusive Worldwide License Agreement for the Development and Commercialisation ff the Ipsens Proprietary CDC25[1] Inhibitor (IRC-083864 or Debio 0931), an Anti-Cancer Agent
2. The Debiopharm Life Sciences Award Goes to Dr Lluis Quintana-Murci for his Novel and Original Research on the Human Evolutionary Genetics of Infection
3. Curis and Debiopharm Sign an Exclusive License Agreement Covering the HSP90 Inhibitor CUDC-305
4. Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic
5. Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours
6. Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions
7. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
8. Japanese Cancer Association and Debiopharm Honour Japanese Research
9. Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations
10. Debiopharm and EPFL Establish an Oncology Chair
11. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... Diego, CA (PRWEB) July 25, 2014 WABC ... For Your Pet with Lorry Young will be hosting ... to talk about stem cell therapy in pets. Dr. ... the benefits of stem cell therapy for pets suffering from ... moving the Regenerative Veterinary Medicine industry forward. , Young has ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Lawrence Livermore ... to Thomson Reuters list of " The World's Most ... part of the 3,000 researchers who were identified by ... recognize those who published the highest-impact work (2002-2012 and ... papers on combustion modeling . , "This recognition ...
(Date:7/25/2014)... July 25, 2014 /PRNewswire-iReach/ -- Xybion Corporation, the ... global corporations operating in highly regulated industries, announced ... annual Global User Group Conference, Xybion International Exchange, ... Philadelphia, Pennsylvania at the Sheraton Society ... This year,s conference theme ...
(Date:7/25/2014)... July 25, 2014 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... June 30, 2014, after market close on Thursday, August 14, ... to the market opening on Friday, August 15, 2014, at ... China Standard Time) to review the Company,s financial results and ...
Breaking Biology Technology:Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2
... of Health, The Infectious Disease Research, Institute and ... of Advisors, SEATTLE, Oct. 7 The ... acquisition of compounds for further,development into tuberculosis (TB) ... SUMM) of Oxfordshire, UK, and the Microbial Chemistry,Research ...
... Oct. 7 BioEnergy International, LLC,(BioEnergy), a ... biochemicals and biofuels, announces the,addition of Norman ... effective December,2008. Mr. Augustine has a record ... level of industry and government culminating in ...
... Oct. 7 Morria Biopharmaceuticals Plc, ... of novel,anti-inflammatory drugs, announced today the ... novel anti-inflammatory drugs using MD Biosciences,Immunoprofiler(TM) ... was specifically,chosen to identify and assess ...
Cached Biology Technology:Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 2Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 3Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 4Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 5BioEnergy International, LLC Announces Norman R. Augustine to Join Advisory Board 2BioEnergy International, LLC Announces Norman R. Augustine to Join Advisory Board 3Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds 2
(Date:7/28/2014)... CITY (July 28, 2014)The Brain & Behavior Research ... Klerman and Freedman Prizes, recognizing exceptional clinical and ... supported by NARSAD Young Investigator Grants. The grants ... in neurobiological and psychosocial research for the prevention, ... that affect one in four people. , Six ...
(Date:7/28/2014)... Research and Markets has announced ... America 2014-2018" report to their offering. ... and analyze biological data. These systems capture biological traits ... patterns, and hand measurements from the subject and compare ... main purpose of a biometrics system is to identify ...
(Date:7/28/2014)... from fertility problems, many of these due to genetic ... expect such genes, which reduce an individual,s ability to ... Weizmann Institute of Science that recently appeared in ... Not only can it explain the high rates of ... understanding the causes of genetic diseases and their treatment. ...
Breaking Biology News(10 mins):The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 4Biometrics Market in Latin America 2014-2018 2Mutations from Venus, mutations from Mars 2
... has evolved a unique technique for sensing motion may inspire ... active sonar. Although members of the fish ... environment and the movement of water around them with gel-covered ... underwater objects and navigate through their lightless environment inspired a ...
... a traffic accident with personal injury is significantly higher ... use of codeine alone does not carry an increased ... Norwegian Institute of Public Health. Codeine and ... mild to moderate pain. In Norway, codeine is included ...
... 2009 / b3c newswire / -  LabRoots Inc. ... social networking site for the scientific community. Beginning today, ... to LabRoots.com to begin building relationships with other scientists ... from giving scientists a place to share their expertise ...
Cached Biology News:Researchers develop flow sensors based on hair structures of blind cavefish 2Researchers develop flow sensors based on hair structures of blind cavefish 3Codeine use and accident risk 2LabRoots Launches Social Networking Site for Scientists & Engineers 2
The SVT3-2 diverter valve is a 3-port, 2-position valve for use with the BioLogic DuoFlow system....
... The PROTEAN II xi multi-cell is for 2-D ... efficient cooling capabilities. The PROTEAN II xi multi-cell ... comb, type of glass plates, and cooling system. ... converted to the PROTEAN II XL multi-cell for ...
... II xi cell, 16 cm, is used for ... proteins in agarose gels. The cell is supplied ... central cooling core with gaskets, lower buffer chamber, ... 4 sandwich clamps, upper buffer dam, casting stand ...
CleanCut agarose is used to prepare genomic DNA plugs for use in pulsed field gel electrophoresis (PFGE) applications. Supplied as a 12 ml solution of 2% agarose....
Biology Products: